文献速递甲状腺核医学肿瘤 PET/CT

转移性分化型甲状腺癌124I PET/CT最佳显像时间研究

Optimal Time for 124I PET/CT Imaging in Metastatic Differentiated Thyroid Cancer.
PubMed 文献 · Clin Nucl Med · 2021-01-01

本研究纳入9例疑似转移的分化型甲状腺癌患者,共分析45次124I PET/CT扫描,在给药后2、24、48、72、96小时进行显像。视觉评估显示48小时扫描检出病灶数最多,双时间点显像优于单时间点(97% vs 87%),结论推荐48+72小时或48+96小时双时间点方案。

要点

  • 48小时单时间点显像病灶检出率最高,双时间点(48+72或48+96小时)优于单时间点。
  • 24与48小时扫描间总病灶数及远处转移数差异有统计学意义(P<0.05)。
  • 若48小时扫描阴性或感兴趣区无摄取,可加做72或96小时扫描;疑肺转移可考虑72或96小时。

核心结论

  • 124I PET/CT双时间点显像优于任何单时间点显像(P<0.10)。
  • 基于视觉评估,48+72小时或48+96小时双时间点病灶检出率最高,单时间点中48小时检出率最高。

研究设计与样本

  • 前瞻性研究,纳入9例疑似转移的分化型甲状腺癌患者,低碘饮食及促甲状腺激素刺激准备后口服31.5或62.9 MBq(0.85或1.7 mCi)124I。
  • 给药后4天内进行124I PET及低剂量定位CT,共回顾45次扫描,由2名核医学医师独立判读。

主要发现

  • 视觉评估共识别31个可疑转移灶,2小时见6个、24小时18个、48小时27个、72小时24个、96小时20个。
  • 24与48小时扫描间总病灶数(局部和远处转移)及远处转移数差异有统计学意义(P<0.05)。
  • 24、48、72小时扫描检出的局部病灶数相同,48小时扫描显示的远处转移灶多于其他时间点。
  • 定量分析中,中位ACRmean/AA在24和48小时最高,中位病灶/本底比值因病灶位置而异,肺转移最高值在72和96小时。

关键数值与推荐

  • 双时间点显像检出率97%,单时间点显像87%(P<0.10)。
  • 视觉评分采用半定量3级评分:1级轻度摄取、2级中度摄取、3级浓聚摄取。

临床怎么用

  • 推荐采用48+72小时或48+96小时双时间点124I PET/CT以提高病灶检出率。
  • 若48小时扫描完全阴性或感兴趣区无124I摄取,可加做72或96小时扫描。
  • 疑似肺转移时,可考虑在72或96小时追加显像。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The objective of this study was to determine the optimal time for 124I PET/CT imaging to maximize the detection of locoregional and/or distant metastases of differentiated thyroid cancer. METHODS: Differentiated thyroid cancer patients suspected of having metastatic disease were prepared with low-iodine diet and appropriate thyroid-stimulating hormone stimulation. 124I PET and low-dose localization CT were performed over 4 days after oral administration of 31.5 or 62.9 MBq (0.85 or 1.7 mCi) of 124I. Each scan was independently reviewed by 2 nuclear medicine physicians. All foci of activity were categorized, and the visual intensity of uptake was scored by a semiquantitative 3-point grading system (1: mild uptake, 2: moderate uptake, 3: intense uptake). Lesion volumes were determined on the CT image or on the PET images. Background (bkg) was also measured for each lesion and on each individual PET image. For each lesion, the mean activity concentration rate per unit administered activity (ACRmean/AA) and lesion-to-bkg ratios were compared across the 5 different time points. The semiquantitative grade and the quantitative measurements were compared. RESULTS: A total of 45 124I PET/CT scans were reviewed for 9 patients. In the visual assessment, a total of 31 foci suggestive for or highly suggestive of metastasis were identified on 124I PET/CT. Of these, 6 were seen on the 2-h, 18 on the 24-h, 27 on the 48-h, 24 on the 72-h, and 20 on the 96-h scan. There was a significant difference between the 24- and 48-h scans in the total number of foci (ie, locoregional and distant metastasis) (P < 0.05) and in the number of distant metastases (P < 0.05). The 24-, 48-, and 72-h scans identified the same number of locoregional foci. The 48-h scan visualized more of the distant metastases than any other time point. 124I PET/CT with dual-time-point imaging was superior to single-time-point imaging (97% vs 87%). In the quantitative analysis, the median ACRmean/AA was highest at 24 and 48 h, and the median lesion-to-bkg ratio was variable for different lesion locations. For lung metastases, the highest median lesion-to-bkg ratio was at 72 and 96 h. CONCLUSIONS: 124I PET/CT with dual-time-point imaging was superior to any single-time-point imaging (P < 0.10). Based on the visual assessment, dual time points at 48 + 72 h or 48 + 96 h yielded the highest lesion detection rate, whereas for single-time-point imaging, the 48-h images had the highest lesion detection rate. If the 48-h scan is completely negative or has negative 124I uptake in the region of interest, then a 72- or 96-h scan may be valuable. If lung metastases are suspected, then one should consider additional imaging at 72 or 96 h.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Wu D, Plyku D, Kulkarni K, et al. Optimal Time for 124I PET/CT Imaging in Metastatic Differentiated Thyroid Cancer. Clin Nucl Med. 2021. PMID: 33492859. doi:10.1097/RLU.0000000000003505

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。